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Abstract 
Transgenic mice carrying amyotrophic lateral sclerosis (ALS)-linked superoxide dismutase 1 (SOD1) mutations develop a moto- 
neuron disease resembling human ALS. c-Jun is a transcription factor frequently induced in injured neurons. In this study we have 
examined the distribution of c-Jun-immunoreactivity in the brainstem and spinal cord of transgenic SOD1 mice with a glycine 93 
alanine (G93A) mutation. In non-transgenic l ttermates c-Jun immunostaining was predominantly situated in motoneurons. The number 
of c-Jun immunoreactive motoneuron was reduced in SODl(G93A) mice due to pronounced loss of motoneurons. In SODl(G93A) 
mice, however, c-Jun-immunoreactivity was strongly induced in neurons in the intermediate zone (Rexed's laminae V-VIII and X) of 
the spinal cord and throughout the brainstem reticular formation. These findings are of interest since increased levels of c-jun also have 
been found in the intermediate zone of the spinal cord of ALS patients. Thus c-Jun may be involved in the neurodegenerative processes 
both in ALS and in motoneuron disease in SODI (G93A) mice. 
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In approximately 20% of the patients with the familial 
form of amyotrophic lateral sclerosis (FALS) (i.e. N2% of 
all amyotrophic lateral sclerosis (ALS) cases) the disease 
has been linked to missense mutations in the cytosolic 
copper/zinc superoxide dismutase (SOD1) gene [14]. 
Transgenic mice carrying FALS-l inked mutated human 
SOD1 (hSOD1), but not those with wild-type hSOD1, 
develop a progressive motoneuron disease resembling 
human ALS [5,13,16]. Since the symptoms and patholo- 
gical features of sporadic ALS and FALS are virtually 
indistinguishable it has been assumed that sporadic ALS 
and FALS may share common mechanisms of pathogen- 
esis downstream of a primary defect. This would mean that 
identification of pathogenic mechanisms in transgenic 
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SOD1 mice is relevant not only for SODl- l inked ALS, 
but also for sporadic ALS which is responsible for more 
than 90% of the patients. 
The transcription factor c-Jun has been implicated in the 
control of neuronal death and regeneration [4,7,12]. The 
expression of c-Jun can be induced in neurons by various 
types of injury [3,7,12]. Recently, it has been reported that 
the spinal cords of patients with sporadic ALS display a 3 -  
4-fold increase of expression of c-jun mRNA [15], sug- 
gesting that c-Jun is involved in the neurodegenerative 
processes of ALS. In this immunocytochemical study we 
have investigated whether changes in c-Jun expression 
occur in the brains of transgenic mice expressing ALS- 
linked mutated hSOD1. 
Transgenic mice derived from the Gurney Gl- l ine car- 
rying hSOD1 with a glycine93-to-alanine (G93A) mutation 
[5] were obtained from The Jackson Lab. (Bar Harbor, 
ME, USA; strain designation B6SJL-TgN(SOD1- 
G93A)Gur). In our animal facility, mice were backcrossed 
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to either a C57B16 or a FVB background, by mating hemi- 
zygote transgenic males with inbred C57B16 (Harlan, 
Zeist, The Netherlands) or outbred FVB females (Harlan, 
Zeist, The Netherlands). Transgenic progeny was identi- 
fied by polymerase chain reaction (PCR) of tail DNA with 
primers specific for hSODI [14], and by immunocyto- 
chemistry with a monoclonal antibody against hSOD1 
(Sigma, St. Louis, USA). At antibody dilutions up to 
1:50000 intense homogeneous immunostaining was 
observed throughout the brain and spinal cord of trans- 
genic mice. No hSODI immunostaining was visible in 
the brains of non-transgenic littermates. 
The transgenic mice derived from The Jackson Lab., as 
well as transgenic C57B16 and FVB backcrosses began to 
develop clinical symptoms at 24-32 weeks of age. They 
had difficulty in extending their hind limbs when lifted by 
their tails, and frequently showed a mild tremor in one or 
more limbs. Subsequently, affected mice showed progres- 
sive weakness of the limbs, and 2 -4  weeks later they were 
visibly smaller and showed disturbed locomotion, with the 
hindlimbs often in hyperflexed or hyperextended position. 
In accordance with previous observations [2,16], trans- 
genic mice developed vacuolar degeneration in axons 
and dendrites. Vacuoles were already present at 20 
weeks of age before the onset of symptoms and were con- 
centrated in motoneuronal cell groups. By the onset of 
clinical symptoms loss of motoneurons, assessed by cho- 
line-acetyltransferase (CHAT) immunocytochemistry, 
became apparent [ 10]. 
Both symptomatic and presymptomatic SOD l(G93A) 
mice and non-transgenic littermates were used in this 
study (Table 1). The mice were deeply anesthetized with 
sodium pentobarbital (60 mg/kg i.p.), and subsequently 
perfused transcardially with phosphate-buffered saline, 
followed by 4% freshly dissolved paraformaldehyde in 
0.12 M phosphate buffer (PB; pH 7.4). The brains were 
post-fixed overnight in the same fixative, and cryopro- 
tected in 30% sucrose in PB for another night. Frozen 40 
mm-thick sections were cut, incubated free-floating for 48 
h at 4°C with antibody against c-Jun (Abl, Oncogene 
sciences) diluted 1:10000 in Tris-buffered saline, and 
stained employing the avidin-biotin-peroxidase complex 
method (ABC; Vector Lab.) with diaminobenzidine 
(0.05%) as the chromogen. Adjacent sections were incu- 
bated with a monoclonal antibody against ChAT (kindly 
provided by Dr. Cozzari [l]) to label motoneurons. The 
brains of transgenic mice were always processed together 
with a control brain, using the same antibody and diami- 
nobenzidine solutions. 
c-Jun immunostaining was confined to nuclei of neu- 
rons. Non-transgenic littermates howed immunolabeled 
neurons in the hippocampus, the piriform cortex, the brain- 
stem and the spinal cord. In the spinal cord, c-Jun immu- 
noreactivity was confined to motoneurons, and in the 
preganglionic sympathetic and parasympathetic neurons. 
50-77% of the motoneurons were c-Jun-positive, the 
majority of which displayed weak-to-moderate c-Jun 
immunoreactivity, whereas a few were strongly labeled 
(Fig. I A and Fig. 2). In the brainstem immunoreactivity 
was predominantly situated in motoneurons of the cranial 
nerve nuclei. Other areas with c-Jun immunoreactive n u- 
rons included the rostral portion of the nucleus of the 
solitary tract, the raphe magnus and the mesencephalic 
nucleus of the trigeminal nerve (Fig. 2A). 
SOD1 (G93A) mice with clinical symptoms displayed a
strikingly different pattern of c-Jun immunolabeling in the 
spinal cord and brainstem (Figs 1 and 2). In the spinal cord 
a large number of neurons with moderately or intensely c- 
Jun-immunostained nuclei were present throughout he 
grey matter. Most neurons with c-Jun-positive nuclei 
were situated in the intermediate zone (Rexed's laminae 
V-V I I I  and X), and were small-to-intermediate in size (8-  
20 mm in diameter). The number of c-Jun-positive neurons 
in the intermediate zone and dorsal horn varied between 
mice (Table l). It roughly correlated with the progression 
of disease, i.e. animals killed at the onset of clinical dis- 
ease showed fewer jun-positive neurons in the intermedi- 
ate zone and dorsal horn than animals with severe muscle 
weakness (Fig. 2B). A few neurons with weakly c-Jun 
positive nuclei were observed in the intermediate zone 
Table I 
Number of c-Jun-immunoreactive neurons in the intermediate zone (IZ) and dorsal horn (DH), and c-Jun-immunoreactive motoneurons in transverse 
sections of the L4 segment of the spinal cord of control and SODI(G93A) mice, killed before or after onset of symptoms 
Mouse groups (n) Age c-Jun-positivc c-Jun-positivc ChAT-positive c-Jun-positive 
(weeks) neurons in IZ motoneurons motoneurons motoneurons/ 
and DH ChAT-positive 
motoneurons (%) 
Non-transgenic littermates (5) 24 32 0 32 + 2 (27 36) 53 + 3 (47 60) 62 + 6 (50-77) 
Pre-symptomatic ODI(G93A) 21 24 4 _+ 5 (0-12) 31 + 3 (27 36) 46 _+ 2 (41~:[9) 68 + 2 (66-73) 
mice 3) 
Symptomatic SODI(G93A) 25 34 82+12(38-144)*  14+-1(9 19)* 25+_2(19 35)* 53_+4(44 68) 
mice (7) 
Adjacent sections were processed for ChAT-immunocytochemistry to determine the total number of motoneurons/section. Values represent means _+ SE 
(range). Values are based on countings of four adjacent series of L4 sections/animal immunostained for c-Jun and CHAT, respectively. *P < 10 5 
compared to non-transgenic l ttermates, unpaired t-test. 
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lary, pontine and mesencephalic reticular formation pre- 
dominantly in its medial part (Fig. 2A). The c-Jun-positive 
neurons in the reticular formation varied in size and 
included very large (>25 mm in diameter) neurons. 
Labeled neurons generally were more numerous in the 
medullary reticular formation than in the pontine and 
mesencephalic reticular formation. Other brainstem 
regions consistently showing c-Jun positive neurons 
included the deep cerebellar nuclei, the lateral vestibular 
nuclei, the red nucleus, the dorsal and most lateral part of 
the periaquaductal grey and the deep layers of the superior 
colliculus. No changes in c-Jun expression were observed 
in the cerebellar cortex, and in diencephalic and telence- 
phalic brain regions of symptomatic SODl(G93A) mice. 
In pre-symptomatic SOD1 (G93A) mice the distribution of 
c-Jun expression i  the brainstem was identical as in non- 
transgenic littermates. 
In the present study we have shown that c-Jun-immu- 
noreactivity is strongly expressed in the brainstem and 
spinal cord of symptomatic SODl(G93A) mice. c-Jun 
expression was not induced in pre-symptomatic 
SODl(G93A) mice. This demonstrates that c-Jun induc- 
tion is not a direct consequence of transgene xpression, 
but is related specifically to the degenerative process 
caused by the mutated SOD1 gene. c-Jun immunolabeling 
in control mice was consistent with previous descriptions 
in rat [6], and did not occur in neurons known in rat to 
A case 34 (control) case 47 
Fig. I. Distribution of c-Jun immunoreactivity n the ventral horn and 
intermediate zone of the L4 spinal cord of a non-transgenic l ttermate 
(A) and a SOD l(G93A) transgenic mouse (B). (C) High magnification of
insert in (B). Note strongly c-Jun-positive neuronal nuclei in the inter- 
mediate zone of SODI(G93A) L4 spinal cord (arrows in (C)). Dashed 
lines in (A) and (B) indicate the border between the grey and the white 
matter. Scale bars, (A,B) 100 #m; (C) 25 p.m. 
of the lumbar spinal cord of one of the presymptomatic 
SODl(G93A) mice. C-Jun-positive neurons other than 
motoneurons, preganglionic sympathetic and parasympa- 
thetic neurons, however, were never seen in the other pre- 
symptomatic SOD1 (G93A) mice nor in control mice. 
Spinal motoneurons of the symptomatic SODl(G93A) 
mice generally displayed higher levels of c-Jun immunor- 
eactivity than those of control mice (Fig. 1A,B). The num- 
ber of spinal motoneurons expressing c-Jun 
immunoreactivity, however, was reduced in symptomatic 
SODl(G93A) mice (Table 1). This reduction in the num- 
ber of c-Jun-positive motoneurons was proportional to the 
amount of motoneuron loss (Table 1). 
In the brainstem of symptomatic SODl(G93A) mice, c- 
Jun-positive neurons were present hroughout the medul- 
/~!, ,-:'" • ",~'~.")) 
1 mm 
B case 34 (control) case  43  case 47 
L4 
1 mm 
Fig. 2. Drawing of transverse 40 p.m sections of control (case 34) and 
transgenic SODl(G93A) mice (cases 43 and 47) showing the distribution 
of c-Jun immunoreactive nuclei n the rostral and caudal medulla (A) and 
the spinal cord C7 and L4 segments (B). 7, Facial nucleus; 12, hypo- 
glossal nucleus; 4V, fourth ventricle; Amb, ambiguus; AIN, anterior 
interposed nucleus; Co, cochlear nucleus; icp, inferior cerebellar pedun- 
cle; IO, inferior olive; LCN, lateral cerebellar nucleus; MCN, medial 
cerebellar nucleus; py, pyramidal tract; Sp5C and Sp50, spinal nucleus 
of the trigeminal nerve pars caudalis, and pars oralis, respectively. 
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constitutively express other members of  the jun-family,  
e.g. the hippocampal CA1 area, which contain junB- and 
junD-posit ive cells [6]. Hence, it is unlikely that c-Jun 
immunoreact iv i ty in symptomatic SOD(G93A)  mice is 
due to crossreactivity of the antibody with junB and junD. 
The presence of  numerous c- Jun- immunoreact ive n u- 
rons in the intermediate zone of the spinal cord of  sympto- 
matic SODl (G93A)  mice is in line with data of  Virgo and 
Bel leroche [15] showing that the level of c-jun mRNA is 
increased in the lumbar spinal cord of  patients with spora- 
dic ALS,  in particular in the intermediate zone. This sug- 
gests that motoneuron disease in SODl (G93A)  mice has 
mechanisms in common with sporadic ALS,  and that inter- 
mediate zone neurons are involved in disease process of  
ALS.  
Many neurons in the intermediate zone of the spinal 
cord project directly to motoneurons [11]. The brainstem 
areas displaying c-Jun-posit ive neurons in symptomatic 
SOD I(G93A) mice also contain neurons with direct pro- 
ject ions to motoneurons in the spinal cord or the brainstem 
[8,9]. Inhibition of  axonal transport and axon transection 
have shown to induce high c-Jun expression levels, sug- 
gesting that c-Jun expression is regulated by a target- 
derived signal [7,12]. Accordingly,  in SODl (G93A)  
mice, c-Jun expression may have been retrogradely 
induced in 'premotoneurons '  as a consequence of moto- 
neuron degeneration. 
c-Jun expression has been associated both with preven- 
tion and induction of  neuronal death [4,7,12]. In a recent 
study employing a silver staining method specific for 
degenerating neurons, we have shown that argyrophil ic 
neuronal degeneration occur in all areas, that according 
to the present study contain c-Jun positive neurons [10]. 
This suggests that the induction of c-Jun expression is 
connected with the degeneration of these neurons. 
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